New CAR-T therapy shows promise for tough leukemia in Real-World study
Disease control
Not yet recruiting
This study will follow 200 Chinese patients with relapsed or refractory B-cell acute lymphoblastic leukemia who receive a CAR-T cell therapy called puzolcabtagene autoleucel. The goal is to see how well it works in everyday medical practice, measuring response rates and how long …
Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC